Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
Rossi AB, Herlaar E, Braselmann S, Huynh S, Taylor V, Frances R, Issakani SD, Argade A, Singh R, Payan DG, Masuda ES. Rossi AB, et al. Among authors: payan dg. J Allergy Clin Immunol. 2006 Sep;118(3):749-55. doi: 10.1016/j.jaci.2006.05.023. Epub 2006 Jul 28. J Allergy Clin Immunol. 2006. PMID: 16950297
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. Braselmann S, et al. Among authors: payan dg. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. doi: 10.1124/jpet.106.109058. Epub 2006 Aug 31. J Pharmacol Exp Ther. 2006. PMID: 16946104 Clinical Trial.
Application of cultured human mast cells (CHMC) for the design and structure-activity relationship of IgE-mediated mast cell activation inhibitors.
Argade A, Bhamidipati S, Li H, Carroll D, Clough J, Keim H, Sylvain C, Rossi AB, Coquilla C, Issakani SD, Masuda ES, Payan DG, Singh R. Argade A, et al. Among authors: payan dg. Bioorg Med Chem Lett. 2015;25(10):2117-21. doi: 10.1016/j.bmcl.2015.03.075. Epub 2015 Mar 31. Bioorg Med Chem Lett. 2015. PMID: 25872982
Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling.
Argade A, Bhamidipati S, Li H, Sylvain C, Clough J, Carroll D, Keim H, Braselmann S, Taylor V, Zhao H, Herlaar E, Issakani SD, Wong BR, Masuda ES, Payan DG, Singh R. Argade A, et al. Among authors: payan dg. Bioorg Med Chem Lett. 2015;25(10):2122-8. doi: 10.1016/j.bmcl.2015.03.072. Epub 2015 Apr 1. Bioorg Med Chem Lett. 2015. PMID: 25891105
A novel role for p21-activated protein kinase 2 in T cell activation.
Chu PC, Wu J, Liao XC, Pardo J, Zhao H, Li C, Mendenhall MK, Pali E, Shen M, Yu S, Taylor VC, Aversa G, Molineaux S, Payan DG, Masuda ES. Chu PC, et al. Among authors: payan dg. J Immunol. 2004 Jun 15;172(12):7324-34. doi: 10.4049/jimmunol.172.12.7324. J Immunol. 2004. PMID: 15187108
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
McLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y, Franci C, Lang D, Pali E, Lasaga J, Low C, Zhao F, Chang B, Gururaja TL, Xu W, Baluom M, Sweeny D, Carroll D, Sran A, Thota S, Parmer M, Romane A, Clemens G, Grossbard E, Qu K, Jenkins Y, Kinoshita T, Taylor V, Holland SJ, Argade A, Singh R, Pine P, Payan DG, Hitoshi Y. McLaughlin J, et al. Among authors: payan dg. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. doi: 10.1007/s00432-009-0641-1. J Cancer Res Clin Oncol. 2010. PMID: 19609559
181 results